Site-specific modification of ED-B-targeting antibody using intein-fusion technology

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Möhlmann, Sina ^a   Bringmann, Peter ^b   Greven, Simone ^a   Harrenga, Axel ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; CANCER THERAPY; COUPLING CHEMISTRY; CYTOTOXIC AGENTS; DRUG LOAD; EXPRESSED PROTEIN LIGATION; FUNCTIONALIZED; FUSION PROTEINS; HEAVY CHAIN; HETEROGENEOUS PRODUCTS; HIGH HOMOGENEITY; HIGH YIELD; IN-VITRO; KEY PARAMETERS; REDUCING CONDITIONS; SITE-SPECIFIC; SITE-SPECIFIC MODIFICATIONS; TARGET PROTEINS; TRANS-SPLICING;

ANTIBODIES;

ANTIBODY CONJUGATE; BIOTIN; CYSTEINE; FIBRONECTIN; FIBRONECTIN ED B; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; INTEIN; LYSINE; PROTEIN MXE GYRA; PROTEIN NPU DNAE; UNCLASSIFIED DRUG; ED B FIBRONECTIN PROTEIN, HUMAN; ED-B FIBRONECTIN PROTEIN, HUMAN;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; BIOTECHNOLOGY; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG SYNTHESIS; EXPRESSED PROTEIN LIGATION; HUMAN; HUMAN CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEIN TRANSSPLICING; SITE SPECIFIC MODIFICATION; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ENGINEERING; TRANS SPLICING;

AMINO ACID SEQUENCE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRONECTINS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INTEINS; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TRANS-SPLICING;

EID: 79960555564     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-76     Document Type: Article

References (37)

1. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009, 157:220-233. 10.1111/j.1476-5381.2009.00190.x, 2697811, 19459844.
2. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003, 30:3-8.
3. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60-70.
4. Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene 2007, 26:3644-3653. 10.1038/sj.onc.1210380, 17530018.
5. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008, 14:154-169. 10.1097/PPO.0b013e318172d704, 18536555.
6. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005, 9:491-500. 10.1517/14728222.9.3.491, 15948669.
7. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102:75-85. 10.1002/ijc.10662, 12353237.
8. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9:571-579.
9. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274. 10.1182/blood-2008-06-160416, 19131554.
10. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F. The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010,
11. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146. 10.1038/nbt1141, 16151407.
12. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070. 10.1158/1078-0432.CCR-04-0789, 15501986.
13. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, Carter P. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006, 19:299-307. 10.1093/protein/gzl013, 16644914.
14. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932. 10.1038/nbt.1480, 18641636.
15. O'Shannessy DJ, Quarles RH. Labeling of the oligosaccharide moieties of immunoglobulins. J Immunol Methods 1987, 99:153-161. 10.1016/0022-1759(87)90120-7, 3035026.
16. Stan AC, Radu DL, Casares S, Bona CA, Brumeanu TD. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res 1999, 59:115-121.
17. Scheck RA, Francis MB. Regioselective labeling of antibodies through N-terminal transamination. ACS Chem Biol 2007, 2:247-251. 10.1021/cb6003959, 17455901.
18. Wu P, Shui W, Carlson BL, Hu N, Rabuka D, Lee J, Bertozzi CR. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc Natl Acad Sci USA 2009, 106:3000-3005. 10.1073/pnas.0807820106, 2651276, 19202059.
19. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673. 10.1126/science.1129594, 16888140.
20. Sunbul M, Yin J. Site specific protein labeling by enzymatic posttranslational modification. Org Biomol Chem 2009, 7:3361-3371. 10.1039/b908687k, 19675886.
21. Saleh L, Perler FB. Protein splicing in cis and in trans. Chem Rec 2006, 6:183-193. 10.1002/tcr.20082, 16900466.
22. Muir TW, Sondhi D, Cole PA. Expressed protein ligation: A general method for protein engineering. Proc Natl Acad Sci USA 1998, 95:6705-6710. 10.1073/pnas.95.12.6705, 22605, 9618476.
23. Muir TW. Semisynthesis of proteins by expressed protein ligation. Annu Rev Biochem 2003, 72:249-289. 10.1146/annurev.biochem.72.121801.161900, 12626339.
24. Wu H, Hu Z, Liu XQ. Protein trans-splicing by a split intein encoded in a split DnaE gene of Synechocystis sp. PCC6803. Proc Natl Acad Sci USA 1998, 95:9226-9231. 10.1073/pnas.95.16.9226, 21320, 9689062.
25. Evans TC, Martin D, Kolly R, Panne D, Sun L, Ghosh I, Chen L, Benner J, Liu XQ, Xu MQ. Protein trans-splicing and cyclization by a naturally split intein from the dnaE gene of Synechocystis species PCC6803. J Biol Chem 2000, 275:9091-9094. 10.1074/jbc.275.13.9091, 10734038.
26. Mootz HD. Split inteins as versatile tools for protein semisynthesis. Chembiochem 2009, 10:2579-2589. 10.1002/cbic.200900370, 19708049.
27. Sydor JR, Mariano M, Sideris S, Nock S. Establishment of intein-mediated protein ligation under denaturing conditions: C-terminal labeling of a single-chain antibody for biochip screening. Bioconjug Chem 2002, 13:707-712. 10.1021/bc025534z, 12121124.
28. Reulen SWA, van Baal I, Raats JMH, Merkx M. Efficient, chemoselective synthesis of immunomicelles using single-domain antibodies with a C-terminal thioester. BMC Biotechnol 2009, 9:66. 10.1186/1472-6750-9-66, 2719619, 19619333.
29. Chaisemartin L, Chinestra P, Favre G, Blonski C, Faye JC. Synthesis and application of a N-1' fluorescent biotinyl derivative inducing the specific carboxy-terminal dual labeling of a novel RhoB-selective scFv. Bioconjug Chem 2009, 20:847-855. 10.1021/bc800272r, 19348471.
30. Telenti A, Southworth M, Alcaide F, Daugelat S, Jacobs WR, Perler FB. The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. J Bacteriol 1997, 179:6378-6382. 179553, 9335286.
31. Evans TC, Benner J, Xu MQ. Semisynthesis of cytotoxic proteins using a modified protein splicing element. Protein Sci 1998, 7:2256-2264. 10.1002/pro.5560071103, 2143866, 9827992.
32. Iwai H, Züger S, Jin J, Tam PH. Highly efficient protein trans-splicing by a naturally split DnaE intein from Nostoc punctiforme. FEBS Lett 2006, 580:1853-1858. 10.1016/j.febslet.2006.02.045, 16516207.
33. Aranko AS, Züger S, Buchinger E, Iwaï H. In vivo and in vitro protein ligation by naturally occurring and engineered split DnaE inteins. PLoS ONE 2009, 4:e5185. 10.1371/journal.pone.0005185, 2664965, 19365564.
34. Andrew SM, Titus JA. Fragmentation of immunoglobulin G. Curr Protoc Cell Biol 2003, Chapter 16:Unit 16.4.
35. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007, 58:221-237. 10.1146/annurev.med.58.070605.115320, 17059365.
36. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273:21769-21776. 10.1074/jbc.273.34.21769, 9705314.
37. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002, 30:E9. 10.1093/nar/30.2.e9, 99848, 11788735.